Terms: = Ovarian cancer AND ROS1, ROS, 6098, ENSG00000047936, P08922, MCF3, RP1-179P9_1
38375 results:
1. Dual‑regulated oncolytic adenovirus carrying
Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
[TBL] [Abstract] [Full Text] [Related]
2. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
[TBL] [Abstract] [Full Text] [Related]
3. When to reinvite initially ineligible populations for targeted lung cancer screening?
Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
[TBL] [Abstract] [Full Text] [Related]
4. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
5. Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in cancer: A Systematic Review and Meta-Analysis.
Gao L; Fan J; He J; Che X; Wang X; Han C
Technol Cancer Res Treat; 2024; 23():15330338241245939. PubMed ID: 38752263
[TBL] [Abstract] [Full Text] [Related]
6. CircAGFG1 Promotes ovarian cancer Progression Through the miR-409-3 p/ZEB1 Axis.
Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
[TBL] [Abstract] [Full Text] [Related]
8. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
[TBL] [Abstract] [Full Text] [Related]
9. FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer.
Kluz-Barłowska M; Kluz T; Paja W; Pancerz K; Łączyńska-Madera M; Miziak P; Cebulski J; Depciuch J
Sci Rep; 2024 May; 14(1):11025. PubMed ID: 38744861
[TBL] [Abstract] [Full Text] [Related]
10. IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3/HIF-1α pathway.
Guo QY; Song JN; Chen YM; Yuan HN; Xue WS; Sun Y; Niu XL; Wang Y; Chen X
Med Oncol; 2024 May; 41(6):155. PubMed ID: 38744773
[TBL] [Abstract] [Full Text] [Related]
11. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.
Zhang J; Yang J; Li X; Mao L; Zhang Y; Liu Y; Bao Y
Mol Genet Genomics; 2024 May; 299(1):51. PubMed ID: 38743077
[TBL] [Abstract] [Full Text] [Related]
12. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
Marius W; Leticia OF; Friedrich KN; Stephan M; Louisa H; Tabea S; Elisa S; Pauline W; Yi D; Qi M; Barbara S; Carsten B; Walter F; Jasmin W; Franziska B
Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
[TBL] [Abstract] [Full Text] [Related]
13. Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.
Zhao Y; Li X; Loscalzo J; Smelik M; Sysoev O; Wang Y; Mahmud AKMF; Mansour Aly D; Benson M
J Transl Med; 2024 May; 22(1):444. PubMed ID: 38734658
[TBL] [Abstract] [Full Text] [Related]
14. Blood Lead Level as Marker of Increased Risk of ovarian cancer in BRCA1 Carriers.
Kiljańczyk A; Matuszczak M; Marciniak W; Derkacz R; Stempa K; Baszuk P; Bryśkiewicz M; Lubiński K; Cybulski C; Dębniak T; Gronwald J; Huzarski T; Lener MR; Jakubowska A; Szwiec M; Stawicka-Niełacna M; Godlewski D; Prusaczyk A; Jasiewicz A; Kluz T; Tomiczek-Szwiec J; Kilar-Kobierzycka E; Siołek M; Wiśniowski R; Posmyk R; Jarkiewicz-Tretyn J; Sun P; Scott RJ; Narod SA; Lubiński J
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732616
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in cancer.
Shreenivas A; Nishizaki D; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Kato S; Kurzrock R
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731962
[TBL] [Abstract] [Full Text] [Related]
16. Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis.
Alsalek S; Schwarzmann KB; Budhathoki S; Hernandez-Lopez V; Smith JB; Li BH; Langer-Gould A
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200255. PubMed ID: 38728608
[TBL] [Abstract] [Full Text] [Related]
17. Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study.
Zhao J; Wang D; Wang R; He Y; Jia C; Pan L; Ma S; Wu M; Wang W; Cheng X; Yang J; Xiang Y
J Ovarian Res; 2024 May; 17(1):96. PubMed ID: 38720349
[TBL] [Abstract] [Full Text] [Related]
18. Risk of Subsequent Primary cancers Among Adult-Onset 5-Year cancer Survivors in South Korea: Retrospective Cohort Study.
Choi YY; Lee M; Kim EH; Lee JE; Jung I; Cheong JH
JMIR Public Health Surveill; 2024 May; 10():e48380. PubMed ID: 38717807
[TBL] [Abstract] [Full Text] [Related]
19. [Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures].
Gromova OA; Filimonova MV; Torshin IY; Frolova DЕ
Ter Arkh; 2024 Apr; 96(3):266-272. PubMed ID: 38713042
[TBL] [Abstract] [Full Text] [Related]
20. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in ovarian cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract] [Full Text] [Related]
[Next]
